>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
布地奈德联合肺表面活性物质对伴有宫内感染NRDS患儿CC16与SP-A表达的影响
作者:袁二伟  张雅静  曲海新  许津莉  王玲玲  郭华贤 
单位:河北北方学院附属第一医院 儿内科, 河北 张家口 075000
关键词:布地奈德 肺表面活性物质 呼吸窘迫综合征 细胞分泌蛋白16 肺表面活性蛋白A 
分类号:R563.8;R725.6
出版年·卷·期(页码):2019·38·第二期(347-350)
摘要:

目的:探讨布地奈德联合肺表面活性物质(PS)对患有宫内感染新生儿呼吸窘迫综合征(NRDS)患儿细胞分泌蛋白16(CC16)与肺表面活性蛋白A (SP-A)表达的影响。方法:100例宫内感染NRDS患儿根据随机数字表法分为观察组和对照组,每组50例;对照组进行PS治疗,观察组进行布地奈德加PS治疗;比较两组临床疗效,治疗前后的血气指标、血清CC16与SP-A水平。结果:观察组的总有效率为90.0%,显著高于对照组的74.0%(P<0.05)。治疗后两组血气指标显著改善,且观察组血氧分压(PaO2)、氧合指数(OI)显著高于对照组,血二氧化碳分压(PaCO2)显著低于对照组(P<0.05)。治疗后两组血清CC16、SP-A显著降低(P<0.05),且观察组显著低于对照组(P<0.05)。观察组机械通气率和支气管肺发育不良发生率显著低于对照组(P<0.05)。结论:布地奈德联合PS能有效提高宫内感染NRDS的临床疗效,降低血清CC16、SP-A水平。

Objective:To analyze the effect of budesonide combined pulmonary surfactant (PS) in treating intrauterine infection neonatal respiratory distress syndrome (NRDS) children and the influence on serum Clara cell secretory protein 16 (CC16), surfacetant protein-A (SP-A). Methods:100 NRDS children were randomly divided into control group and observation group(n=50). Control group was treated with PS, observation group was treated with budesonide combined PS. The clinical effect, QI-blood indexes, serum CC16, SP-A were compared. Results:The effective rate of observation group was 90.0%, which was higher than that of control group (74.0%, P<0.05). After treatment, QI-blood indexes of both groups were improved, but observation group's PaO2, OI were higher than those of control group,PaCO2 was lower than that of control group(P<0.05). After treatment, both groups' serum CC16, SP-A were decreased(P<0.05), and that of observation group was significantly lower(P<0.05). The mechanical ventilation rate and bronchopulmonary dysplasia rate of observation group were significantly lower (P<0.05). Conclusion:Budesonide combined PS can improve the clinical effect, decrease serum CC16, SP-A.

参考文献:

[1] WANG J,LIU X,ZHU T,et al.Analysis of neonatal respiratory distress syndrome among different gestational segments[J].Int J ClinExp Med,2015,8(9):16273-16279.
[2] YEH T F,CHEN C M,WU S Y,et al.Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia[J].Am J Respir Crit Care Med,2016,193(1):86-95.
[3] 王冉,张巧,马千里,等.血清学生物标志物对急性呼吸窘迫综合征进展及预后的预测研究[J].第三军医大学学报,2017,39(19):1926-1932.
[4] 李政.肺表面活性蛋白A、D水平监测在间质性肺疾病诊治中的临床价值[J].临床和实验医学杂志,2017,16(2):173-175.
[5] 胡亚美,江载芳,陆华,等.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2012:458-461.
[6] 邵肖梅,叶鸿瑁,丘小汕.实用新生儿学[M].4版.北京:人民卫生出版社,2011:395-398.
[7] SWEENEY R M,MCAULEY D F.Acute respiratory distress syndrome[J].Lancet,2016,388(10058):2416-2430.
[8] 穆静.呼吸支持对新生儿呼吸窘迫综合征治疗效果及危险因素分析[J].现代医学,2014,42(9):1051-1054.
[9] 曹冰冰,黄为民.糖皮质激素防治新生儿支气管肺发育不良利弊研究进展[J].中国妇幼保健,2016,31(7):1557-1560.
[10] FENG Y,KUMAR P,WANG J,et al.Dexamethasone but not the equivalent doses of hydrocortisone induces neurotoxicity in neonatal ratbrain[J].Pediatr Res,2015,77(5):618-624.
[11] 陈海英,乔娅.布地奈德联合特布他林雾化吸入对小儿支原体肺炎的疗效及对肺功能的影响[J].现代医学,2018,46(10):1115-1118.
[12] BARRETTE A M,ROBERTS J K,CHAPIN C,et al.Antiinflammatory effects of budesonide in human fetal lung[J].Am J Respir Cell Mol Biol,2016,55(5):623-632.
[13] 吕丽辉,杨玉波,付言杰,等.血清CC-16水平用于ARDS患者预后的临床价值研究[J].医学研究杂志,2017,46(7):140-145.
[14] 张辉果,王晓利,董志巧,等.感染性肺炎患儿血清及灌洗液中肺表面活性蛋白及炎性介质水平的变化研究[J].中华医院感染学杂志,2017,27(3):663-666.
[15] YANG C F,LIN C H,CHIOU S Y,et al.Intratracheal budesonide supplementation in addition to surfactant improves pulmonary outcome in surfactant-depleted newborn piglets[J].PediatrPulmonol,2013,48(2):151-159.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 418347 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364